1	HLA-DR-	hla-dr-	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	CD33+	cd33+	_	_	_	_	_	_	_
4	,	,	_	_	_	_	_	_	_
5	CD56+	cd56+	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	CD16-	cd16-	_	_	_	_	_	_	_
8	myeloid/natural	myeloid/natural	_	_	_	_	_	_	_
9	killer	killer	_	_	_	_	_	_	_
10	cell	cell	_	_	_	_	_	_	_
11	acute	acute	_	_	_	_	_	_	_
12	leukemia	leukemia	_	_	_	_	_	_	_
13	:	:	_	_	_	_	_	_	_
14	a	a	_	_	_	_	_	_	_
15	previously	previously	_	_	_	_	_	_	_
16	unrecognized	unrecognized	_	_	_	_	_	_	_
17	form	form	_	_	_	_	_	_	_
18	of	of	_	_	_	_	_	_	_
19	acute	acute	_	_	_	_	_	_	_
20	leukemia	leukemia	_	_	_	_	_	_	_
21	potentially	potentially	_	_	_	_	_	_	_
22	misdiagnosed	misdiagnose	_	_	_	_	_	_	_
23	as	as	_	_	_	_	_	_	_
24	French-American-British	french-american-british	_	_	_	_	_	_	_
25	acute	acute	_	_	_	_	_	_	_
26	myeloid	myeloid	_	_	_	_	_	_	_
27	leukemia-M3	leukemia-m3	_	_	_	_	_	_	_
28	[	[	_	_	_	_	_	_	_
29	see	see	_	_	_	_	_	_	_
30	comments	comment	_	_	_	_	_	_	_
31	]	]	_	_	_	_	_	_	_
32	We	we	_	_	_	_	_	_	_
33	have	have	_	_	_	_	_	_	_
34	identified	identify	_	_	_	_	_	_	_
35	and	and	_	_	_	_	_	_	_
36	characterized	characterize	_	_	_	_	_	_	_
37	a	a	_	_	_	_	_	_	_
38	previously	previously	_	_	_	_	_	_	_
39	unrecognized	unrecognized	_	_	_	_	_	_	_
40	form	form	_	_	_	_	_	_	_
41	of	of	_	_	_	_	_	_	_
42	acute	acute	_	_	_	_	_	_	_
43	leukemia	leukemia	_	_	_	_	_	_	_
44	that	that	_	_	_	_	_	_	_
45	shares	share	_	_	_	_	_	_	_
46	features	feature	_	_	_	_	_	_	_
47	of	of	_	_	_	_	_	_	_
48	both	both	_	_	_	_	_	_	_
49	myeloid	myeloid	_	_	_	_	_	_	_
50	and	and	_	_	_	_	_	_	_
51	natural	natural	_	_	_	_	_	_	_
52	killer	killer	_	_	_	_	_	_	_
53	(	(	_	_	_	_	_	_	_
54	NK	NK	_	_	_	_	_	_	_
55	)	)	_	_	_	_	_	_	_
56	cells	cell	_	_	_	_	_	_	_
57	.	.	_	_	_	_	_	_	_

1	From	from	_	_	_	_	_	_	_
2	a	a	_	_	_	_	_	_	_
3	consecutive	consecutive	_	_	_	_	_	_	_
4	series	series	_	_	_	_	_	_	_
5	of	of	_	_	_	_	_	_	_
6	350	350	_	_	_	_	_	_	_
7	cases	case	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	adult	adult	_	_	_	_	_	_	_
10	de	de	_	_	_	_	_	_	_
11	novo	novo	_	_	_	_	_	_	_
12	acute	acute	_	_	_	_	_	_	_
13	myeloid	myeloid	_	_	_	_	_	_	_
14	leukemia	leukemia	_	_	_	_	_	_	_
15	(	(	_	_	_	_	_	_	_
16	AML	AML	_	_	_	_	_	_	_
17	)	)	_	_	_	_	_	_	_
18	,	,	_	_	_	_	_	_	_
19	we	we	_	_	_	_	_	_	_
20	identified	identify	_	_	_	_	_	_	_
21	20	20	_	_	_	_	_	_	_
22	cases	case	_	_	_	_	_	_	_
23	(	(	_	_	_	_	_	_	_
24	6	6	_	_	_	_	_	_	_
25	%	%	_	_	_	_	_	_	_
26	)	)	_	_	_	_	_	_	_
27	with	with	_	_	_	_	_	_	_
28	a	a	_	_	_	_	_	_	_
29	unique	unique	_	_	_	_	_	_	_
30	immunophenotype	immunophenotype	_	_	_	_	_	_	_
31	:	:	_	_	_	_	_	_	_
32	CD33+	cd33+	_	_	_	_	_	_	_
33	,	,	_	_	_	_	_	_	_
34	CD56+	cd56+	_	_	_	_	_	_	_
35	,	,	_	_	_	_	_	_	_
36	CD11a+	cd11a+	_	_	_	_	_	_	_
37	,	,	_	_	_	_	_	_	_
38	CD13lo	cd13lo	_	_	_	_	_	_	_
39	,	,	_	_	_	_	_	_	_
40	CD15lo	cd15lo	_	_	_	_	_	_	_
41	,	,	_	_	_	_	_	_	_
42	CD34+/-	cd34+/-	_	_	_	_	_	_	_
43	,	,	_	_	_	_	_	_	_
44	HLA-DR-	hla-dr-	_	_	_	_	_	_	_
45	,	,	_	_	_	_	_	_	_
46	CD16-	cd16-	_	_	_	_	_	_	_
47	.	.	_	_	_	_	_	_	_

1	Multicolor	multicolor	_	_	_	_	_	_	_
2	flow	flow	_	_	_	_	_	_	_
3	cytometric	cytometric	_	_	_	_	_	_	_
4	assays	assay	_	_	_	_	_	_	_
5	confirmed	confirm	_	_	_	_	_	_	_
6	the	the	_	_	_	_	_	_	_
7	coexpression	coexpression	_	_	_	_	_	_	_
8	of	of	_	_	_	_	_	_	_
9	myeloid	myeloid	_	_	_	_	_	_	_
10	(	(	_	_	_	_	_	_	_
11	CD33	CD33	_	_	_	_	_	_	_
12	,	,	_	_	_	_	_	_	_
13	CD13	CD13	_	_	_	_	_	_	_
14	,	,	_	_	_	_	_	_	_
15	CD15	CD15	_	_	_	_	_	_	_
16	)	)	_	_	_	_	_	_	_
17	and	and	_	_	_	_	_	_	_
18	NK	NK	_	_	_	_	_	_	_
19	cell-associated	cell-associated	_	_	_	_	_	_	_
20	(	(	_	_	_	_	_	_	_
21	CD56	CD56	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	antigens	antigen	_	_	_	_	_	_	_
24	in	in	_	_	_	_	_	_	_
25	each	each	_	_	_	_	_	_	_
26	case	case	_	_	_	_	_	_	_
27	,	,	_	_	_	_	_	_	_
28	whereas	whereas	_	_	_	_	_	_	_
29	reverse	reverse	_	_	_	_	_	_	_
30	transcription	transcription	_	_	_	_	_	_	_
31	polymerase	polymerase	_	_	_	_	_	_	_
32	chain	chain	_	_	_	_	_	_	_
33	reaction	reaction	_	_	_	_	_	_	_
34	(	(	_	_	_	_	_	_	_
35	RT-PCR	RT-PCR	_	_	_	_	_	_	_
36	)	)	_	_	_	_	_	_	_
37	assays	assay	_	_	_	_	_	_	_
38	confirmed	confirm	_	_	_	_	_	_	_
39	the	the	_	_	_	_	_	_	_
40	identity	identity	_	_	_	_	_	_	_
41	of	of	_	_	_	_	_	_	_
42	CD56	CD56	_	_	_	_	_	_	_
43	(	(	_	_	_	_	_	_	_
44	neural	neural	_	_	_	_	_	_	_
45	cell	cell	_	_	_	_	_	_	_
46	adhesion	adhesion	_	_	_	_	_	_	_
47	molecule	molecule	_	_	_	_	_	_	_
48	)	)	_	_	_	_	_	_	_
49	in	in	_	_	_	_	_	_	_
50	leukemic	leukemic	_	_	_	_	_	_	_
51	blasts	blast	_	_	_	_	_	_	_
52	.	.	_	_	_	_	_	_	_

1	Although	although	_	_	_	_	_	_	_
2	two	two	_	_	_	_	_	_	_
3	cases	case	_	_	_	_	_	_	_
4	expressed	express	_	_	_	_	_	_	_
5	CD4	cd4	_	_	_	_	_	_	_
6	,	,	_	_	_	_	_	_	_
7	no	no	_	_	_	_	_	_	_
8	case	case	_	_	_	_	_	_	_
9	expressed	express	_	_	_	_	_	_	_
10	CD2	cd2	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	CD3	CD3	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	or	or	_	_	_	_	_	_	_
15	CD8	cd8	_	_	_	_	_	_	_
16	and	and	_	_	_	_	_	_	_
17	no	no	_	_	_	_	_	_	_
18	case	case	_	_	_	_	_	_	_
19	showed	show	_	_	_	_	_	_	_
20	clonal	clonal	_	_	_	_	_	_	_
21	rearrangement	rearrangement	_	_	_	_	_	_	_
22	of	of	_	_	_	_	_	_	_
23	genes	gene	_	_	_	_	_	_	_
24	encoding	encode	_	_	_	_	_	_	_
25	the	the	_	_	_	_	_	_	_
26	T-cell	t-cell	_	_	_	_	_	_	_
27	receptor	receptor	_	_	_	_	_	_	_
28	(	(	_	_	_	_	_	_	_
29	TCR	TCR	_	_	_	_	_	_	_
30	beta	beta	_	_	_	_	_	_	_
31	,	,	_	_	_	_	_	_	_
32	gamma	gamma	_	_	_	_	_	_	_
33	,	,	_	_	_	_	_	_	_
34	delta	delta	_	_	_	_	_	_	_
35	)	)	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	Leukemic	leukemic	_	_	_	_	_	_	_
2	blasts	blast	_	_	_	_	_	_	_
3	in	in	_	_	_	_	_	_	_
4	the	the	_	_	_	_	_	_	_
5	majority	majority	_	_	_	_	_	_	_
6	of	of	_	_	_	_	_	_	_
7	cases	case	_	_	_	_	_	_	_
8	shared	share	_	_	_	_	_	_	_
9	unique	unique	_	_	_	_	_	_	_
10	morphologic	morphologic	_	_	_	_	_	_	_
11	features	feature	_	_	_	_	_	_	_
12	(	(	_	_	_	_	_	_	_
13	deeply	deeply	_	_	_	_	_	_	_
14	invaginated	invaginated	_	_	_	_	_	_	_
15	nuclear	nuclear	_	_	_	_	_	_	_
16	membranes	membrane	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	scant	scant	_	_	_	_	_	_	_
19	cytoplasm	cytoplasm	_	_	_	_	_	_	_
20	with	with	_	_	_	_	_	_	_
21	fine	fine	_	_	_	_	_	_	_
22	azurophilic	azurophilic	_	_	_	_	_	_	_
23	granularity	granularity	_	_	_	_	_	_	_
24	,	,	_	_	_	_	_	_	_
25	and	and	_	_	_	_	_	_	_
26	finely	finely	_	_	_	_	_	_	_
27	granular	granular	_	_	_	_	_	_	_
28	Sudan	Sudan	_	_	_	_	_	_	_
29	black	black	_	_	_	_	_	_	_
30	B	b	_	_	_	_	_	_	_
31	and	and	_	_	_	_	_	_	_
32	myeloperoxidase	myeloperoxidase	_	_	_	_	_	_	_
33	cytochemical	cytochemical	_	_	_	_	_	_	_
34	reactivity	reactivity	_	_	_	_	_	_	_
35	)	)	_	_	_	_	_	_	_
36	that	that	_	_	_	_	_	_	_
37	were	be	_	_	_	_	_	_	_
38	remarkably	remarkably	_	_	_	_	_	_	_
39	similar	similar	_	_	_	_	_	_	_
40	to	to	_	_	_	_	_	_	_
41	those	those	_	_	_	_	_	_	_
42	of	of	_	_	_	_	_	_	_
43	acute	acute	_	_	_	_	_	_	_
44	promyelocytic	promyelocytic	_	_	_	_	_	_	_
45	leukemia	leukemia	_	_	_	_	_	_	_
46	(	(	_	_	_	_	_	_	_
47	APL	APL	_	_	_	_	_	_	_
48	)	)	_	_	_	_	_	_	_
49	;	;	_	_	_	_	_	_	_
50	particularly	particularly	_	_	_	_	_	_	_
51	the	the	_	_	_	_	_	_	_
52	microgranular	microgranular	_	_	_	_	_	_	_
53	variant	variant	_	_	_	_	_	_	_
54	(	(	_	_	_	_	_	_	_
55	FAB	FAB	_	_	_	_	_	_	_
56	AML-M3v	AML-M3v	_	_	_	_	_	_	_
57	)	)	_	_	_	_	_	_	_
58	.	.	_	_	_	_	_	_	_

1	However	however	_	_	_	_	_	_	_
2	,	,	_	_	_	_	_	_	_
3	all	all	_	_	_	_	_	_	_
4	20	20	_	_	_	_	_	_	_
5	cases	case	_	_	_	_	_	_	_
6	lacked	lack	_	_	_	_	_	_	_
7	the	the	_	_	_	_	_	_	_
8	t(15;17)	t(15;17)	_	_	_	_	_	_	_
9	and	and	_	_	_	_	_	_	_
10	17	17	_	_	_	_	_	_	_
11	cases	case	_	_	_	_	_	_	_
12	tested	test	_	_	_	_	_	_	_
13	lacked	lack	_	_	_	_	_	_	_
14	the	the	_	_	_	_	_	_	_
15	promyelocytic/retinoic	promyelocytic/retinoic	_	_	_	_	_	_	_
16	acid	acid	_	_	_	_	_	_	_
17	receptor	receptor	_	_	_	_	_	_	_
18	alpha	alpha	_	_	_	_	_	_	_
19	(	(	_	_	_	_	_	_	_
20	RAR	RAR	_	_	_	_	_	_	_
21	alpha	alpha	_	_	_	_	_	_	_
22	)	)	_	_	_	_	_	_	_
23	fusion	fusion	_	_	_	_	_	_	_
24	transcript	transcript	_	_	_	_	_	_	_
25	in	in	_	_	_	_	_	_	_
26	RT-PCR	RT-PCR	_	_	_	_	_	_	_
27	assays	assay	_	_	_	_	_	_	_
28	;	;	_	_	_	_	_	_	_
29	12	12	_	_	_	_	_	_	_
30	cases	case	_	_	_	_	_	_	_
31	had	have	_	_	_	_	_	_	_
32	46,XX	46,xx	_	_	_	_	_	_	_
33	or	or	_	_	_	_	_	_	_
34	46,XY	46,xy	_	_	_	_	_	_	_
35	karyotypes	karyotype	_	_	_	_	_	_	_
36	,	,	_	_	_	_	_	_	_
37	whereas	whereas	_	_	_	_	_	_	_
38	2	2	_	_	_	_	_	_	_
39	cases	case	_	_	_	_	_	_	_
40	had	have	_	_	_	_	_	_	_
41	abnormalities	abnormality	_	_	_	_	_	_	_
42	of	of	_	_	_	_	_	_	_
43	chromosome	chromosome	_	_	_	_	_	_	_
44	17q	17q	_	_	_	_	_	_	_
45	:	:	_	_	_	_	_	_	_
46	1	1	_	_	_	_	_	_	_
47	with	with	_	_	_	_	_	_	_
48	del(17)(q25)	del(17)(q25)	_	_	_	_	_	_	_
49	and	and	_	_	_	_	_	_	_
50	the	the	_	_	_	_	_	_	_
51	other	other	_	_	_	_	_	_	_
52	with	with	_	_	_	_	_	_	_
53	t(11;17)(q23;q21)	t(11;17)(q23;q21)	_	_	_	_	_	_	_
54	and	and	_	_	_	_	_	_	_
55	the	the	_	_	_	_	_	_	_
56	promyelocytic	promyelocytic	_	_	_	_	_	_	_
57	leukemia	leukemia	_	_	_	_	_	_	_
58	zinc	zinc	_	_	_	_	_	_	_
59	finger/RAR	finger/RAR	_	_	_	_	_	_	_
60	alpha	alpha	_	_	_	_	_	_	_
61	fusion	fusion	_	_	_	_	_	_	_
62	transcript	transcript	_	_	_	_	_	_	_
63	.	.	_	_	_	_	_	_	_

1	All	all	_	_	_	_	_	_	_
2	cases	case	_	_	_	_	_	_	_
3	tested	test	_	_	_	_	_	_	_
4	(	(	_	_	_	_	_	_	_
5	6/20	6/20	_	_	_	_	_	_	_
6	)	)	_	_	_	_	_	_	_
7	,	,	_	_	_	_	_	_	_
8	including	include	_	_	_	_	_	_	_
9	the	the	_	_	_	_	_	_	_
10	case	case	_	_	_	_	_	_	_
11	with	with	_	_	_	_	_	_	_
12	t(11;17)	t(11;17)	_	_	_	_	_	_	_
13	,	,	_	_	_	_	_	_	_
14	failed	fail	_	_	_	_	_	_	_
15	to	to	_	_	_	_	_	_	_
16	differentiate	differentiate	_	_	_	_	_	_	_
17	in	in	_	_	_	_	_	_	_
18	vitro	vitro	_	_	_	_	_	_	_
19	in	in	_	_	_	_	_	_	_
20	response	response	_	_	_	_	_	_	_
21	to	to	_	_	_	_	_	_	_
22	all-trans	all-trans	_	_	_	_	_	_	_
23	retinoic	retinoic	_	_	_	_	_	_	_
24	acid	acid	_	_	_	_	_	_	_
25	(	(	_	_	_	_	_	_	_
26	ATRA	ATRA	_	_	_	_	_	_	_
27	)	)	_	_	_	_	_	_	_
28	,	,	_	_	_	_	_	_	_
29	suggesting	suggest	_	_	_	_	_	_	_
30	that	that	_	_	_	_	_	_	_
31	these	these	_	_	_	_	_	_	_
32	cases	case	_	_	_	_	_	_	_
33	may	may	_	_	_	_	_	_	_
34	account	account	_	_	_	_	_	_	_
35	for	for	_	_	_	_	_	_	_
36	some	some	_	_	_	_	_	_	_
37	APLs	APL	_	_	_	_	_	_	_
38	that	that	_	_	_	_	_	_	_
39	have	have	_	_	_	_	_	_	_
40	not	not	_	_	_	_	_	_	_
41	shown	show	_	_	_	_	_	_	_
42	a	a	_	_	_	_	_	_	_
43	clinical	clinical	_	_	_	_	_	_	_
44	response	response	_	_	_	_	_	_	_
45	to	to	_	_	_	_	_	_	_
46	ATRA	ATRA	_	_	_	_	_	_	_
47	.	.	_	_	_	_	_	_	_

1	Four	four	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	6	6	_	_	_	_	_	_	_
4	cases	case	_	_	_	_	_	_	_
5	tested	test	_	_	_	_	_	_	_
6	showed	show	_	_	_	_	_	_	_
7	functional	functional	_	_	_	_	_	_	_
8	NK	NK	_	_	_	_	_	_	_
9	cell-mediated	cell-mediated	_	_	_	_	_	_	_
10	cytotoxicity	cytotoxicity	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	suggesting	suggest	_	_	_	_	_	_	_
13	a	a	_	_	_	_	_	_	_
14	relationship	relationship	_	_	_	_	_	_	_
15	between	between	_	_	_	_	_	_	_
16	these	these	_	_	_	_	_	_	_
17	unique	unique	_	_	_	_	_	_	_
18	CD33+	cd33+	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	CD56+	cd56+	_	_	_	_	_	_	_
21	,	,	_	_	_	_	_	_	_
22	CD16-	cd16-	_	_	_	_	_	_	_
23	acute	acute	_	_	_	_	_	_	_
24	leukemias	leukemia	_	_	_	_	_	_	_
25	and	and	_	_	_	_	_	_	_
26	normal	normal	_	_	_	_	_	_	_
27	CD56+	cd56+	_	_	_	_	_	_	_
28	,	,	_	_	_	_	_	_	_
29	CD16-	cd16-	_	_	_	_	_	_	_
30	NK	NK	_	_	_	_	_	_	_
31	precursor	precursor	_	_	_	_	_	_	_
32	cells	cell	_	_	_	_	_	_	_
33	.	.	_	_	_	_	_	_	_

1	Using	use	_	_	_	_	_	_	_
2	a	a	_	_	_	_	_	_	_
3	combination	combination	_	_	_	_	_	_	_
4	of	of	_	_	_	_	_	_	_
5	panning	panning	_	_	_	_	_	_	_
6	and	and	_	_	_	_	_	_	_
7	multiparameter	multiparameter	_	_	_	_	_	_	_
8	flow	flow	_	_	_	_	_	_	_
9	cytometric	cytometric	_	_	_	_	_	_	_
10	sorting	sorting	_	_	_	_	_	_	_
11	,	,	_	_	_	_	_	_	_
12	we	we	_	_	_	_	_	_	_
13	identified	identify	_	_	_	_	_	_	_
14	a	a	_	_	_	_	_	_	_
15	normal	normal	_	_	_	_	_	_	_
16	CD56+	cd56+	_	_	_	_	_	_	_
17	,	,	_	_	_	_	_	_	_
18	CD33+	cd33+	_	_	_	_	_	_	_
19	,	,	_	_	_	_	_	_	_
20	CD16-	cd16-	_	_	_	_	_	_	_
21	counterpart	counterpart	_	_	_	_	_	_	_
22	cell	cell	_	_	_	_	_	_	_
23	at	at	_	_	_	_	_	_	_
24	a	a	_	_	_	_	_	_	_
25	frequency	frequency	_	_	_	_	_	_	_
26	of	of	_	_	_	_	_	_	_
27	1	1	_	_	_	_	_	_	_
28	%	%	_	_	_	_	_	_	_
29	to	to	_	_	_	_	_	_	_
30	2	2	_	_	_	_	_	_	_
31	%	%	_	_	_	_	_	_	_
32	in	in	_	_	_	_	_	_	_
33	the	the	_	_	_	_	_	_	_
34	peripheral	peripheral	_	_	_	_	_	_	_
35	blood	blood	_	_	_	_	_	_	_
36	of	of	_	_	_	_	_	_	_
37	healthy	healthy	_	_	_	_	_	_	_
38	individuals	individual	_	_	_	_	_	_	_
39	.	.	_	_	_	_	_	_	_

1	Our	our	_	_	_	_	_	_	_
2	studies	study	_	_	_	_	_	_	_
3	suggest	suggest	_	_	_	_	_	_	_
4	that	that	_	_	_	_	_	_	_
5	this	this	_	_	_	_	_	_	_
6	form	form	_	_	_	_	_	_	_
7	of	of	_	_	_	_	_	_	_
8	acute	acute	_	_	_	_	_	_	_
9	leukemia	leukemia	_	_	_	_	_	_	_
10	may	may	_	_	_	_	_	_	_
11	arise	arise	_	_	_	_	_	_	_
12	from	from	_	_	_	_	_	_	_
13	transformation	transformation	_	_	_	_	_	_	_
14	of	of	_	_	_	_	_	_	_
15	a	a	_	_	_	_	_	_	_
16	precursor	precursor	_	_	_	_	_	_	_
17	cell	cell	_	_	_	_	_	_	_
18	common	common	_	_	_	_	_	_	_
19	to	to	_	_	_	_	_	_	_
20	both	both	_	_	_	_	_	_	_
21	the	the	_	_	_	_	_	_	_
22	myeloid	myeloid	_	_	_	_	_	_	_
23	and	and	_	_	_	_	_	_	_
24	NK	NK	_	_	_	_	_	_	_
25	cell	cell	_	_	_	_	_	_	_
26	lineages	lineage	_	_	_	_	_	_	_
27	;	;	_	_	_	_	_	_	_
28	thus	thus	_	_	_	_	_	_	_
29	we	we	_	_	_	_	_	_	_
30	propose	propose	_	_	_	_	_	_	_
31	the	the	_	_	_	_	_	_	_
32	designation	designation	_	_	_	_	_	_	_
33	myeloid/NK	myeloid/nk	_	_	_	_	_	_	_
34	acute	acute	_	_	_	_	_	_	_
35	leukemia	leukemia	_	_	_	_	_	_	_
36	.	.	_	_	_	_	_	_	_

1	Recognition	Recognition	_	_	_	_	_	_	_
2	of	of	_	_	_	_	_	_	_
3	this	this	_	_	_	_	_	_	_
4	new	new	_	_	_	_	_	_	_
5	leukemic	leukemic	_	_	_	_	_	_	_
6	entity	entity	_	_	_	_	_	_	_
7	will	will	_	_	_	_	_	_	_
8	be	be	_	_	_	_	_	_	_
9	important	important	_	_	_	_	_	_	_
10	in	in	_	_	_	_	_	_	_
11	distinguishing	distinguish	_	_	_	_	_	_	_
12	these	these	_	_	_	_	_	_	_
13	ATRA-nonresponsive	atra-nonresponsive	_	_	_	_	_	_	_
14	cases	case	_	_	_	_	_	_	_
15	from	from	_	_	_	_	_	_	_
16	ATRA-responsive	atra-responsive	_	_	_	_	_	_	_
17	true	true	_	_	_	_	_	_	_
18	APL	apl	_	_	_	_	_	_	_
19	.	.	_	_	_	_	_	_	_

